SCHEMBL663622

SCHEMBL663622

CC1CCC(C(C)C)C(C(=O)Nc2ccc(N3CCOCC3)cc2)C1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.64
ALDH1A1 P00352 6/20 0.54
LMNA P02545 2/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 6/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
RAB9A P51151 2/20 0.46
ATM Q13315 1/20 0.46
EPHX1 P07099 1/20 0.46
GLA P06280 1/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073861 1.00 TRPM8 (0.64) TRPM8ALDH1A1LMNAPOLBMAPT
SCHEMBL2628746 0.86 TRPM8 (0.60) TRPM8ALDH1A1LMNAPOLBMAPT
SCHEMBL2628642 0.86 ALDH1A1 (0.59) TRPM8ALDH1A1LMNAPOLBMAPT
SCHEMBL2628686 0.84 KMT2A (0.60) TRPM8ALDH1A1LMNAMAPTGAA
SCHEMBL4817319 0.81 TRPM8 (0.75) TRPM8ALDH1A1MAPTMEN1KMT2A
SCHEMBL4820732 0.81 TRPM8 (0.75) TRPM8ALDH1A1MAPTMEN1KMT2A
SCHEMBL10073486 0.81 TRPM8 (0.75) TRPM8ALDH1A1MAPTMEN1KMT2A
SCHEMBL2628672 0.81 TRPM8 (0.75) TRPM8ALDH1A1MAPTMEN1KMT2A
SCHEMBL2628758 0.80 TRPM8 (0.73) TRPM8MAPTMEN1KMT2ARAB9A
SCHEMBL10073506 0.80 TRPM8 (0.73) TRPM8ALDH1A1POLBGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2012-02-23 US claimed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US claimed
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2012-02-23 US disclosed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US disclosed
US-7868004-B2 Menthane carboxamide derivatives having cooling properties GIVAUDAN S.A. (CH) 2011-01-11 US disclosed
US-20080305051-A1 Menthane Carboxamide Derivatives Having Cooling Properties GIVAUDAN S.A. (CH) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS TSG101, TP53, BAX TRPM8 28/4885ALDH1A1 3429/4885LMNA 1599/4885
US-20080305051-A1 Menthane Carboxamide Derivatives Having Cooling Properties MDH2, ME2, H1-0 TRPM8 72/4885ALDH1A1 819/4885LMNA 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.